{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02410577",
      "orgStudyIdInfo": {
        "id": "15-002"
      },
      "organization": {
        "fullName": "Memorial Sloan Kettering Cancer Center",
        "class": "OTHER"
      },
      "briefTitle": "89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme",
      "officialTitle": "A Pilot Study of 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme"
    },
    "statusModule": {
      "statusVerifiedDate": "2018-08",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2015-04",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2018-08",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2018-08",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2015-04-02",
      "studyFirstSubmitQcDate": "2015-04-02",
      "studyFirstPostDateStruct": {
        "date": "2015-04-07",
        "type": "ESTIMATED"
      },
      "resultsFirstSubmitDate": "2019-02-22",
      "resultsFirstSubmitQcDate": "2019-02-22",
      "resultsFirstPostDateStruct": {
        "date": "2019-03-19",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2019-02-22",
      "lastUpdatePostDateStruct": {
        "date": "2019-03-19",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Memorial Sloan Kettering Cancer Center",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "Weill Medical College of Cornell University",
          "class": "OTHER"
        }
      ]
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme."
    },
    "conditionsModule": {
      "conditions": [
        "Glioblastoma"
      ],
      "keywords": [
        "89Zr-J591",
        "15-002"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "DIAGNOSTIC",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 2,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "89Zr-J591",
          "type": "EXPERIMENTAL",
          "description": "Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.",
          "interventionNames": [
            "Drug: 89Zr-J591",
            "Device: PET/CT Scan",
            "Device: MRI",
            "Other: Blood draw"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "89Zr-J591",
          "description": "The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.",
          "armGroupLabels": [
            "89Zr-J591"
          ]
        },
        {
          "type": "DEVICE",
          "name": "PET/CT Scan",
          "armGroupLabels": [
            "89Zr-J591"
          ]
        },
        {
          "type": "DEVICE",
          "name": "MRI",
          "armGroupLabels": [
            "89Zr-J591"
          ]
        },
        {
          "type": "OTHER",
          "name": "Blood draw",
          "description": "Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.",
          "armGroupLabels": [
            "89Zr-J591"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Binding of 89Zr-J591",
          "description": "This will be measured by J591 uptake in PET scan.",
          "timeFrame": "1 year"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient age \\> 25 years old and \\< 80 years old\n* Patients with reoccurrence of brain tumor\n* The principal investigator or co-PI must review MRI and CT findings based on the radiologic assessment provided they meet the following imaging criteria (as established in the clinical trial 09-177):\n\nOR\n\n* Patients with newly diagnosed GBM and one of the following options:\n* Eligible for surgery after the last research scan.\n* Significant residual disease after initial surgery\n* The principal investigator or co-PI must review MRI and CT findings and agree with the presence of significant residual disease\n* Treatment (non-surgical) naïve\n* Karnofsky Performance Score ≥ 70\n\nExclusion Criteria:\n\n* Laboratory values:\n\n  * Serum creatinine \\>2.5 mg/dL.\n  * AST (SGOT) \\>2.5x ULN.\n  * Bilirubin (total) \\>1.5x ULN.\n  * Serum calcium \\>11 mg/dL.\n* Pregnant or breastfeeding (if a female is of childbearing potential, and unsure of pregnancy status, a standard pregnancy test should be done).\n* If an initial biopsy demonstrates neoplasm other than GBM\n* Presence of any other co-existing condition which, in the judgment of the investigator, might increase the risk to the subject.\n* Presence of serious systemic illness, including: uncontrolled inter-current infection, uncontrolled malignancy, significant renal disease, or psychiatric/social situations, which might limit compliance with study requirements\n* Prior treatment.\n* Other serious illness (es), which might preclude completion of this, study or interfere with determination of causality of any adverse effects experienced in this study.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "26 Years",
      "maximumAge": "79 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Joseph Osborne, MD,PhD",
          "affiliation": "Memorial Sloan Kettering Cancer Center",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Memorial Sloan Kettering Cancer Center",
          "city": "New York",
          "state": "New York",
          "zip": "10065",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "38968568",
          "type": "DERIVED",
          "citation": "McBriar JD, Shafiian N, Scharf S, Boockvar JA, Wernicke AG. Prostate-Specific Membrane Antigen Use in Glioma Management: Past, Present, and Future. Clin Nucl Med. 2024 Sep 1;49(9):806-816. doi: 10.1097/RLU.0000000000005365. Epub 2024 Jul 1."
        }
      ],
      "seeAlsoLinks": [
        {
          "label": "Memorial Sloan Kettering Cancer Center",
          "url": "http://www.mskcc.org/"
        }
      ]
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "groups": [
        {
          "id": "FG000",
          "title": "89Zr-J591",
          "description": "Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.\n\n89Zr-J591: The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.\n\nPET/CT Scan\n\nMRI\n\nBlood draw: Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection."
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "2"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "2"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "89Zr-J591",
          "description": "Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.\n\n89Zr-J591: The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.\n\nPET/CT Scan\n\nMRI\n\nBlood draw: Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection."
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "2"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "FULL_RANGE",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "56",
                      "lowerLimit": "51",
                      "upperLimit": "60"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "2"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "American Indian or Alaska Native",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Asian",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Native Hawaiian or Other Pacific Islander",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Black or African American",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "White",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "2"
                    }
                  ]
                },
                {
                  "title": "More than one race",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Region of Enrollment",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "title": "United States",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "2"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Binding of 89Zr-J591",
          "description": "This will be measured by J591 uptake in PET scan.",
          "populationDescription": "Data were not collected.",
          "reportingStatus": "POSTED",
          "timeFrame": "1 year",
          "groups": [
            {
              "id": "OG000",
              "title": "89Zr-J591",
              "description": "Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.\n\n89Zr-J591: The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.\n\nPET/CT Scan\n\nMRI\n\nBlood draw: Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "0"
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "5",
      "timeFrame": "Up to 1 year",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "89Zr-J591",
          "description": "Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.\n\n89Zr-J591: The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.\n\nPET/CT Scan\n\nMRI\n\nBlood draw: Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.",
          "deathsNumAffected": 2,
          "deathsNumAtRisk": 2,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 2,
          "otherNumAffected": 0,
          "otherNumAtRisk": 2
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": true
      },
      "pointOfContact": {
        "title": "Dr. Joseph Osborne, MD, PhD",
        "organization": "Memorial Sloan Kettering Cancer Center",
        "email": "osbornej@mskcc.org",
        "phone": "212-639-7788"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot_SAP",
          "hasProtocol": true,
          "hasSap": true,
          "hasIcf": false,
          "label": "Study Protocol and Statistical Analysis Plan",
          "date": "2016-09-27",
          "uploadDate": "2019-02-22T11:19",
          "filename": "Prot_SAP_000.pdf",
          "size": 1549523
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-10-28"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D005909",
          "term": "Glioblastoma"
        }
      ],
      "ancestors": [
        {
          "id": "D001254",
          "term": "Astrocytoma"
        },
        {
          "id": "D005910",
          "term": "Glioma"
        },
        {
          "id": "D018302",
          "term": "Neoplasms, Neuroepithelial"
        },
        {
          "id": "D017599",
          "term": "Neuroectodermal Tumors"
        },
        {
          "id": "D009373",
          "term": "Neoplasms, Germ Cell and Embryonal"
        },
        {
          "id": "D009370",
          "term": "Neoplasms by Histologic Type"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D009375",
          "term": "Neoplasms, Glandular and Epithelial"
        },
        {
          "id": "D009380",
          "term": "Neoplasms, Nerve Tissue"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000072078",
          "term": "Positron Emission Tomography Computed Tomography"
        },
        {
          "id": "D001800",
          "term": "Blood Specimen Collection"
        }
      ],
      "ancestors": [
        {
          "id": "D049268",
          "term": "Positron-Emission Tomography"
        },
        {
          "id": "D014055",
          "term": "Tomography, Emission-Computed"
        },
        {
          "id": "D007090",
          "term": "Image Interpretation, Computer-Assisted"
        },
        {
          "id": "D003952",
          "term": "Diagnostic Imaging"
        },
        {
          "id": "D019937",
          "term": "Diagnostic Techniques and Procedures"
        },
        {
          "id": "D003933",
          "term": "Diagnosis"
        },
        {
          "id": "D014057",
          "term": "Tomography, X-Ray Computed"
        },
        {
          "id": "D064847",
          "term": "Multimodal Imaging"
        },
        {
          "id": "D011856",
          "term": "Radiographic Image Enhancement"
        },
        {
          "id": "D007089",
          "term": "Image Enhancement"
        },
        {
          "id": "D010781",
          "term": "Photography"
        },
        {
          "id": "D011859",
          "term": "Radiography"
        },
        {
          "id": "D014056",
          "term": "Tomography, X-Ray"
        },
        {
          "id": "D011877",
          "term": "Radionuclide Imaging"
        },
        {
          "id": "D014054",
          "term": "Tomography"
        },
        {
          "id": "D003947",
          "term": "Diagnostic Techniques, Radioisotope"
        },
        {
          "id": "D013048",
          "term": "Specimen Handling"
        },
        {
          "id": "D019411",
          "term": "Clinical Laboratory Techniques"
        },
        {
          "id": "D011677",
          "term": "Punctures"
        },
        {
          "id": "D013514",
          "term": "Surgical Procedures, Operative"
        },
        {
          "id": "D008919",
          "term": "Investigative Techniques"
        }
      ]
    }
  },
  "hasResults": true
}